AzTrials
AzTrials

Urinary Tract InfectionNCT05880602

Nettle and Cranberry Capsules for Prevention of Urinary Tract Infection

A study testing Nettle and Cranberry complex capsules in people with Urinary Tract Infection, run by Chung Shan Medical University at 1 site in Taiwan.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This study investigates whether the oral intake of a nettle and cranberry complex capsule may prevent recurrent urinary tract infection (rUTI). Participants will be aged between 30 - 75 years of age, with confirmed diagnosis of UTI status. Read more about this study

Who is it for?
Ages 30 to 75 years
Conditions the study is for
Urinary Tract Infection
What is being tested?
Nettle and Cranberry complex capsules
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
60 participants
Where
1 siteTaiwan
Study dates
5 Jul 2023to 31 Dec 2023
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 30 to 75 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • aged between 30 and 75 years
  • at least two episodes in 6 months, or at least three episodes of a UTI in 12 months.

Who cannot join

  • pregnancy women
  • diabetes
  • History of anatomical urogenital anomalies, urogenital tract surgery
  • History of acute or chronic renal failure, nephrolithiasis
  • History of intestinal diseases causing malabsorption
  • Anticoagulant medication in the last month
  • immunocompromise
  • Known allergy or intolerance to cranberry

Trial locations and contacts

1 site in 1 country.

Taiwan1 site

  • Chung Shan Medical University Hospital

    Taichung, 40201

Other trials in Taiwan

About this study

Official title: Clinical Trial of Nettle and Cranberry Capsules for Prevention of Urinary Tract Infection

This study investigates whether the oral intake of a nettle and cranberry complex capsule may prevent recurrent urinary tract infection (rUTI). Participants will be aged between 30 - 75 years of age, with confirmed diagnosis of UTI status. The participants will be assessed for several parameters and asked to take 2 nettle and cranberry complex capsules twice daily for 8 weeks. The parameters will include international prostate symptoms score (IPSS), overactive bladder symptom score (OABSS), international consultation on incontinence questionnaire - overactive bladder (ICIQ-OAB), 3-day bladder diary (3dBD), and urine routine.

Read the detailed description

Urinary tract infections (UTIs) are one of the most common bacterial infections affecting women. UTI occurs in 50-80% of women in the general population. About one in four women with one UTI episode will go on to develop frequent recurrences.

Recurrent urinary tract infection (rUTI) is defined as repeated UTI with a frequency of at least two episodes in the preceding six months or three episodes in the past year. rUTI has been regarded as a substantial global healthcare problem.

This investigation is a randomized, double-blind study. Subjects with confirmed diagnosis of rUTI are randomly assigned to control group or treatment group, and asked to orally intake 2 capsules of either placebo or nettle and cranberry complex capsules twice daily. Participants will be assessed for parameters, including international prostate symptoms score (IPSS) (male only), overactive bladder symptom score (OABSS), international consultation on incontinence questionnaire - overactive bladder (ICIQ-OAB), 3-day bladder diary (3dBD) and urine routine. The assessments are conducted at baseline, 4 weeks, and 8 weeks after the oral intake period. The parameters are used to compare and evaluate whether the nettle and cranberry complex capsule can prevention rUTI.

Being tested
Nettle and Cranberry complex capsules, Placebo(starch)
Keywords
Nettle, Cranberry, Prevention, Urinary Tract Infection, Recurrent Infection, Inflammation
Medical subject headings
Urinary Tract Infections, Reinfection, Inflammation

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Nettle and Cranberry complex capsulesDietary supplement

    A specific capsule product, containing nettle and cranberry complex will be given to participants for oral intake for 8 weeks.

  • Placebo(starch)Dietary supplement

    A specific capsule product, containing starch will be given to participants for oral intake for 8 weeks.

Study groups in NCT05880602
Study groupRoleWhat they receive
ControlPlacebo comparatorSubjects will take two capsule of containing starch, twice a daily for 8 weeks.
Receives: Dietary Supplement: Placebo(starch)
TreatmentExperimentalSubjects will take two capsule of containing nettle and cranberry complex, twice a daily for 8 weeks.
Receives: Dietary Supplement: Nettle and Cranberry complex capsules

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. UTI-free duration in 8 weeks

    Comparing the number of days from the beginning of the study to the first recurrence of UTI, and the number of days from each recurrence to the next recurrence between different treatment groups.

    Measured: on baseline and 8 weeks

  2. UTI recurrent incidence in 8 weeks

    UTI episodes during 8 weeks treatment for each subject

    Measured: 8 weeks

Secondary outcomes (4)

  1. International Prostate Symptom Score (IPSS) Change from Baseline

    The IPSS questionnaire is a tool commonly used to assess the severity of LUTS, and to monitor the progress of the symptoms during treatment. Score range is 0-35, with higher scores indicating increasing symptom severity.

    Measured: on baseline,4 weeks and 8 weeks

  2. Overactive Bladder Symptom Score (OABSS) Change from Baseline

    OABSS is a valid self-assessment questionnaire, with four questions set according to OAB syndrome to determine the severity of OAB, which includes daytime and nighttime urination frequency, urgency, and urge incontinence. Score range is 0-15, with higher scores indicating increasing symptom severity.

    Measured: on baseline,4 weeks and 8 weeks

  3. International Consultation on Incontinence Questionnaire Overactive Bladder Score (ICIQ-OAB) Change from Baseline

    Assessment of quality of life related to the impact of overactive bladder symptoms on daily activities.

    Assessment of quality of life related to the impact of overactive bladder symptoms on daily activities Assessment of quality of life related to the impact of overactive bladder symptoms on daily activities.

    Measured: on baseline,4 weeks, and 8 weeks

  4. Bladder diary

    Assessment of number of voids, number of leakages, and post void residual.

    Measured: on baseline,4 weeks, and 8 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted30 May 2023
  2. Study start5 Jul 2023
  3. Primary completion31 Dec 2023
  4. Study completion31 Dec 2023

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Double blind
Who is masked
Participant, Care provider
Enrolment
60 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05880602
Sponsor's protocol ID
CS2-23025
Status last verified
Sep 2025
First submitted
19 May 2023
Last updated
26 Sep 2025
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No

Publications

  • Stamm WE, Norrby SR. Urinary tract infections: disease panorama and challenges. J Infect Dis. 2001 Mar 1;183 Suppl 1:S1-4. doi: 10.1086/318850. No abstract available.

    PubMed 11171002

  • Harding GK, Ronald AR. The management of urinary infections: what have we learned in the past decade? Int J Antimicrob Agents. 1994 Jun;4(2):83-8. doi: 10.1016/0924-8579(94)90038-8.

    PubMed 18611593

  • Sivick KE, Mobley HL. Waging war against uropathogenic Escherichia coli: winning back the urinary tract. Infect Immun. 2010 Feb;78(2):568-85. doi: 10.1128/IAI.01000-09. Epub 2009 Nov 16.

    PubMed 19917708

  • Foxman B, Barlow R, D'Arcy H, Gillespie B, Sobel JD. Urinary tract infection: self-reported incidence and associated costs. Ann Epidemiol. 2000 Nov;10(8):509-15. doi: 10.1016/s1047-2797(00)00072-7.

    PubMed 11118930

  • Sihra N, Goodman A, Zakri R, Sahai A, Malde S. Nonantibiotic prevention and management of recurrent urinary tract infection. Nat Rev Urol. 2018 Dec;15(12):750-776. doi: 10.1038/s41585-018-0106-x.

    PubMed 30361493

  • Kwok M, McGeorge S, Mayer-Coverdale J, Graves B, Paterson DL, Harris PNA, Esler R, Dowling C, Britton S, Roberts MJ. Guideline of guidelines: management of recurrent urinary tract infections in women. BJU Int. 2022 Nov;130 Suppl 3(Suppl 3):11-22. doi: 10.1111/bju.15756. Epub 2022 May 17.

    PubMed 35579121

  • Fowler CJ, Griffiths D, de Groat WC. The neural control of micturition. Nat Rev Neurosci. 2008 Jun;9(6):453-66. doi: 10.1038/nrn2401.

    PubMed 18490916

  • Guay DR. Cranberry and urinary tract infections. Drugs. 2009;69(7):775-807. doi: 10.2165/00003495-200969070-00002.

    PubMed 19441868

  • Scholes D, Hooton TM, Roberts PL, Stapleton AE, Gupta K, Stamm WE. Risk factors for recurrent urinary tract infection in young women. J Infect Dis. 2000 Oct;182(4):1177-82. doi: 10.1086/315827. Epub 2000 Aug 31.

    PubMed 10979915

  • Wan X, Wu C, Xu D, Huang L, Wang K. Toileting behaviours and lower urinary tract symptoms among female nurses: A cross-sectional questionnaire survey. Int J Nurs Stud. 2017 Jan;65:1-7. doi: 10.1016/j.ijnurstu.2016.10.005. Epub 2016 Oct 21.

    PubMed 28027949

Questions about this trial

What is this clinical trial studying?

A study testing Nettle and Cranberry complex capsules in people with Urinary Tract Infection, run by Chung Shan Medical University at 1 site in Taiwan.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 26 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Taiwan. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

UTI-free duration in 8 weeks (time frame: on baseline and 8 weeks). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05880602, which also lists 10 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Sep 2025.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in